These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 18077209)

  • 1. Low-dose erythropoietin improves cardiac function in experimental heart failure without increasing haematocrit.
    Lipsic E; Westenbrink BD; van der Meer P; van der Harst P; Voors AA; van Veldhuisen DJ; Schoemaker RG; van Gilst WH
    Eur J Heart Fail; 2008 Jan; 10(1):22-9. PubMed ID: 18077209
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Erythropoietin induces neovascularization and improves cardiac function in rats with heart failure after myocardial infarction.
    van der Meer P; Lipsic E; Henning RH; Boddeus K; van der Velden J; Voors AA; van Veldhuisen DJ; van Gilst WH; Schoemaker RG
    J Am Coll Cardiol; 2005 Jul; 46(1):125-33. PubMed ID: 15992646
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Erythropoietin improves cardiac function through endothelial progenitor cell and vascular endothelial growth factor mediated neovascularization.
    Westenbrink BD; Lipsic E; van der Meer P; van der Harst P; Oeseburg H; Du Marchie Sarvaas GJ; Koster J; Voors AA; van Veldhuisen DJ; van Gilst WH; Schoemaker RG
    Eur Heart J; 2007 Aug; 28(16):2018-27. PubMed ID: 17576662
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vascular endothelial growth factor is crucial for erythropoietin-induced improvement of cardiac function in heart failure.
    Westenbrink BD; Ruifrok WP; Voors AA; Tilton RG; van Veldhuisen DJ; Schoemaker RG; van Gilst WH; de Boer RA
    Cardiovasc Res; 2010 Jul; 87(1):30-9. PubMed ID: 20139114
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Erythropoietin stimulates normal endothelial progenitor cell-mediated endothelial turnover, but attributes to neovascularization only in the presence of local ischemia.
    Westenbrink BD; Oeseburg H; Kleijn L; van der Harst P; Belonje AM; Voors AA; Schoemaker RG; de Boer RA; van Veldhuisen DJ; van Gilst WH
    Cardiovasc Drugs Ther; 2008 Aug; 22(4):265-74. PubMed ID: 18327705
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single high-dose intramyocardial administration of erythropoietin promotes early intracardiac proliferation, proves safety and restores cardiac performance after myocardial infarction in rats.
    Gäbel R; Klopsch C; Furlani D; Yerebakan C; Li W; Ugurlucan M; Ma N; Steinhoff G
    Interact Cardiovasc Thorac Surg; 2009 Jul; 9(1):20-5; discussion 25. PubMed ID: 19380336
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined effects of ramipril and angiotensin II receptor blocker TCV116 on rat congestive heart failure after myocardial infarction.
    Tao ZW; Huang YW; Xia Q; Xu QW
    Chin Med J (Engl); 2005 Jan; 118(2):146-54. PubMed ID: 15667801
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Physiological replacement of T3 improves left ventricular function in an animal model of myocardial infarction-induced congestive heart failure.
    Henderson KK; Danzi S; Paul JT; Leya G; Klein I; Samarel AM
    Circ Heart Fail; 2009 May; 2(3):243-52. PubMed ID: 19808346
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Effect of erythropoietin combined with granulocyte-colony stimulating factor in the treatment of acute myocardial infarction in rats].
    Fu ZH; Dong W; Gai LY; Wang F; Ding R; Chen YD
    Nan Fang Yi Ke Da Xue Xue Bao; 2011 Jan; 31(1):17-22. PubMed ID: 21269949
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of darbepoetin alpha on right and left ventricular systolic and diastolic function in anemic patients with chronic heart failure secondary to ischemic or idiopathic dilated cardiomyopathy.
    Parissis JT; Kourea K; Panou F; Farmakis D; Paraskevaidis I; Ikonomidis I; Filippatos G; Kremastinos DT
    Am Heart J; 2008 Apr; 155(4):751.e1-7. PubMed ID: 18371487
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduction of inflammatory cytokine expression and oxidative damage by erythropoietin in chronic heart failure.
    Li Y; Takemura G; Okada H; Miyata S; Maruyama R; Li L; Higuchi M; Minatoguchi S; Fujiwara T; Fujiwara H
    Cardiovasc Res; 2006 Sep; 71(4):684-94. PubMed ID: 16828072
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low-dose therapy with the long-acting erythropoietin analogue darbepoetin alpha persistently activates endothelial Akt and attenuates progressive organ failure.
    Bahlmann FH; Song R; Boehm SM; Mengel M; von Wasielewski R; Lindschau C; Kirsch T; de Groot K; Laudeley R; Niemczyk E; Güler F; Menne J; Haller H; Fliser D
    Circulation; 2004 Aug; 110(8):1006-12. PubMed ID: 15302785
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Alterations in aortic vasomotor function in rats with chronic heart failure and its mechanism].
    Zhang HL; Zhao M; He X; Jiang HK; Yu XJ; Ma X; Zang WJ
    Sheng Li Xue Bao; 2010 Aug; 62(4):317-24. PubMed ID: 20717632
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chronic erythropoietin treatment decreases post-infarct myocardial damage in rats without venous thrombogenic effect.
    Prunier F; Pottier P; Clairand R; Mercier A; Hajjar RJ; Planchon B; Furber A
    Cardiology; 2009; 112(2):129-34. PubMed ID: 18596374
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiplatelet therapy mitigates cardiac remodeling and dysfunction in congestive heart failure due to myocardial infarction.
    Sanganalmath SK; Barta J; Takeda N; Kumamoto H; Dhalla NS
    Can J Physiol Pharmacol; 2008 Apr; 86(4):180-9. PubMed ID: 18418427
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Erythropoietin enhances the therapy potency of autologous bone marrow stromal cells in a rat heart infarction model via phosphatidylinositol-3-kinase/Akt pathway].
    Zhang DG; Zhang FM; Zhang YQ; Zhou F; Gao X; Li CF; Cao KJ
    Zhonghua Xin Xue Guan Bing Za Zhi; 2006 Oct; 34(10):912-6. PubMed ID: 17217721
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The myocardium protective effects of erythropoietin (EPO) in a rat model of asphyxia-induced cardiac arrest/cardiopulmonary resuscitation (CPR)].
    Jiang HL; Zhu YC; Chen XH; Lin PY; Wang HJ
    Zhongguo Wei Zhong Bing Ji Jiu Yi Xue; 2011 Oct; 23(10):608-12. PubMed ID: 22005562
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Direct cardiac actions of erythropoietin (EPO): effects on cardiac contractility, BNP secretion and ischaemia/reperfusion injury.
    Piuhola J; Kerkelä R; Keenan JI; Hampton MB; Richards AM; Pemberton CJ
    Clin Sci (Lond); 2008 Feb; 114(4):293-304. PubMed ID: 17919123
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Erythropoietin, modified to not stimulate red blood cell production, retains its cardioprotective properties.
    Moon C; Krawczyk M; Paik D; Coleman T; Brines M; Juhaszova M; Sollott SJ; Lakatta EG; Talan MI
    J Pharmacol Exp Ther; 2006 Mar; 316(3):999-1005. PubMed ID: 16306273
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [An experimental study of recombinant human erythropoietin on the treatment of acute myocardial infarction in rats].
    Ye L; Du XL; Xia JH; Jiang P; Wang JT; Fan HM; Liu ZM
    Zhonghua Yi Xue Za Zhi; 2006 Oct; 86(39):2776-80. PubMed ID: 17199998
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.